Clinical Trial Update: Melatonin Treatment for Newborn Infants With Moderate to Severe Hypoxic Ischemic Encephalopathy [Phase 1]

View source ↗

Summary

The Phase 1 clinical trial of melatonin for neonatal hypoxic-ischemic encephalopathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neonatal Hypoxic Ischemic Encephalopathy

Drugs mentioned

• Melatonin (melatonin)

Snippet

Sponsor: St. Louis University | Conditions: Newborn Hypoxic Ischemic Encephalopathy | Phase 1 | Status: WITHDRAWN